Where I see patients (1)
Selected research
-
Efficacy of the Allosteric MEK Inhibitor Trametinib in Relapsed and Refractory Juvenile Myelomonocytic Leukemia: a Report from the Children's Oncology Group.
Cancer discovery
-
Targeting high-risk multiple myeloma genotypes with optimized anti-CD70 CAR-T cells.
bioRxiv : the preprint server for biology
-
Desensitization using pegaspargase in the era of commercially available Erwinia: A single-institution report on efficacy, cost, and resource utilization.
Pediatric blood & cancer
Clinical trials
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL...
Improvement in 5-year disease-free survival (DFS) with modified Berlin-Frankfurt-Münster (mBFM) chemotherapy without delayed intensification (DI) part 2 but with inotuzumab ozogamicin, versus full mBFM chemotherapy backbone includ...
Recruiting
More about this studyThe Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in...
The proportion will be calculated as the percent of eligible patients who are identified to have an a priori specified genomic or immunophenotypic target and who enroll on at least one of the sub-trials. The corresponding confiden...
Recruiting
More about this studyInotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or...
The response rate will be estimated using the proportion of eligible/evaluable patients with CR/CRi response. A one-sided lower 95% Agresti-Coull confidence limit will be calculated.
Recruiting
More about this studyContact me
Smell the roses
Wander outside into our Butterfly Garden in Oakland and our healing gardens at Mission Bay.
![](/-/media/project/ucsf/ucsf-bch/images/by-your-side-moment/duck/bys_footer_duck-attentive-2x.jpg?rev=c548d2d5b65147edb278277504c19ae3&hash=87CF39C913D6F38457B7CEE239559D0D)